Insulet [PODD] vs Edwards Lifesciences [EW] Detailed Stock Comparison
Insulet
NASDAQ
Loading...
Edwards Lifesciences
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Insulet wins in 5 metrics, Edwards Lifesciences wins in 14 metrics, with 0 ties. Edwards Lifesciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Insulet | Edwards Lifesciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 94.24 | 32.25 | Edwards Lifesciences |
| Price-to-Book Ratio | 14.87 | 4.30 | Edwards Lifesciences |
| Debt-to-Equity Ratio | 99.49 | 6.62 | Edwards Lifesciences |
| PEG Ratio | -1.07 | -4.92 | Edwards Lifesciences |
| EV/EBITDA | 45.96 | 24.10 | Edwards Lifesciences |
| Profit Margin (TTM) | 10.01% | 72.96% | Edwards Lifesciences |
| Operating Margin (TTM) | 18.66% | 28.12% | Edwards Lifesciences |
| EBITDA Margin (TTM) | 18.66% | 28.12% | Edwards Lifesciences |
| Return on Equity | 19.18% | 15.53% | Insulet |
| Return on Assets (TTM) | 7.75% | 8.42% | Edwards Lifesciences |
| Free Cash Flow (TTM) | $296.30M | $259.90M | Insulet |
| 1-Year Return | 34.47% | 12.61% | Insulet |
| Price-to-Sales Ratio (TTM) | 9.22 | 7.96 | Edwards Lifesciences |
| Enterprise Value | $22.09B | $41.95B | Edwards Lifesciences |
| EV/Revenue Ratio | 9.36 | 7.38 | Edwards Lifesciences |
| Gross Profit Margin (TTM) | 69.67% | 77.52% | Edwards Lifesciences |
| Revenue per Share (TTM) | $34 | $10 | Insulet |
| Earnings per Share (Diluted) | $3.28 | $2.39 | Insulet |
| Beta (Stock Volatility) | 1.40 | 1.05 | Edwards Lifesciences |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Insulet vs Edwards Lifesciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Insulet | 0.56% | 1.53% | -10.33% | 4.24% | 22.33% | 22.04% |
| Edwards Lifesciences | 0.21% | -1.35% | -4.35% | 0.04% | 11.19% | 5.69% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Insulet | 34.47% | 41.76% | 26.22% | 914.07% | 1,872.62% | 1,964.89% |
| Edwards Lifesciences | 12.61% | -6.92% | -10.09% | 204.32% | 581.96% | 2,098.28% |
News Based Sentiment: Insulet vs Edwards Lifesciences
Insulet
News based Sentiment: MIXED
Insulet reported exceptional Q2 results and raised guidance, indicating strong growth. However, a Goldman Sachs price target cut and insider selling created market headwinds, resulting in a mixed investment narrative. The combination of positive financial performance and negative market reactions makes this a significant month for the company.
Edwards Lifesciences
News based Sentiment: MIXED
October brought a mix of positive and negative developments for Edwards Lifesciences. Analyst upgrades and promising clinical trial data were offset by regulatory scrutiny and cost-cutting measures. The overall narrative suggests a company navigating a dynamic environment with both opportunities and challenges, making it a significant month for investors to assess.
Performance & Financial Health Analysis: Insulet vs Edwards Lifesciences
| Metric | PODD | EW |
|---|---|---|
| Market Information | ||
| Market Cap | $22.61B | $45.77B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 676,650 | 4,646,590 |
| 90 Day Avg. Volume | 637,977 | 4,354,680 |
| Last Close | $313.45 | $76.72 |
| 52 Week Range | $225.37 - $353.50 | $64.01 - $83.00 |
| % from 52W High | -11.33% | -7.57% |
| All-Time High | $353.50 (Sep 09, 2025) | $131.73 (Dec 27, 2021) |
| % from All-Time High | -11.33% | -41.76% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.33% | 0.12% |
| Quarterly Earnings Growth | -0.88% | -0.09% |
| Financial Health | ||
| Profit Margin (TTM) | 0.10% | 0.73% |
| Operating Margin (TTM) | 0.19% | 0.28% |
| Return on Equity (TTM) | 0.19% | 0.16% |
| Debt to Equity (MRQ) | 99.49 | 6.62 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $20.78 | $17.94 |
| Cash per Share (MRQ) | $15.93 | $6.92 |
| Operating Cash Flow (TTM) | $516.20M | $794.90M |
| Levered Free Cash Flow (TTM) | $112.66M | $1.26B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Insulet vs Edwards Lifesciences
| Metric | PODD | EW |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 94.24 | 32.25 |
| Forward P/E | 79.87 | 31.46 |
| PEG Ratio | -1.07 | -4.92 |
| Price to Sales (TTM) | 9.22 | 7.96 |
| Price to Book (MRQ) | 14.87 | 4.30 |
| Market Capitalization | ||
| Market Capitalization | $22.61B | $45.77B |
| Enterprise Value | $22.09B | $41.95B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 9.36 | 7.38 |
| Enterprise to EBITDA | 45.96 | 24.10 |
| Risk & Other Metrics | ||
| Beta | 1.40 | 1.05 |
| Book Value per Share (MRQ) | $20.78 | $17.94 |
Financial Statements Comparison: Insulet vs Edwards Lifesciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PODD | EW |
|---|---|---|
| Revenue/Sales | $569.00M | $1.41B |
| Cost of Goods Sold | $160.00M | $301.60M |
| Gross Profit | $409.00M | $1.11B |
| Research & Development | $59.60M | $254.60M |
| Operating Income (EBIT) | $88.80M | $409.90M |
| EBITDA | $118.50M | $461.60M |
| Pre-Tax Income | $48.10M | $433.90M |
| Income Tax | $12.70M | $70.30M |
| Net Income (Profit) | $35.40M | $356.40M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PODD | EW |
|---|---|---|
| Cash & Equivalents | $1.28B | $3.14B |
| Total Current Assets | $2.33B | $6.21B |
| Total Current Liabilities | $520.40M | $1.39B |
| Long-Term Debt | $1.61B | $675.70M |
| Total Shareholders Equity | $1.33B | $10.19B |
| Retained Earnings | $75.70M | $13.53B |
| Property, Plant & Equipment | N/A | $1.80B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PODD | EW |
|---|---|---|
| Operating Cash Flow | $81.00M | $294.00M |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | $48.10M | $224.40M |
| Debt Repayment | $-182.70M | N/A |
| Common Stock Repurchase | N/A | $-258.60M |
Short Interest & Institutional Ownership Analysis
| Metric | PODD | EW |
|---|---|---|
| Shares Short | 1.50M | 7.26M |
| Short Ratio | 2.75 | 1.86 |
| Short % of Float | 0.03% | 0.01% |
| Average Daily Volume (10 Day) | 676,650 | 4,646,590 |
| Average Daily Volume (90 Day) | 637,977 | 4,354,680 |
| Shares Outstanding | 70.20M | 588.60M |
| Float Shares | 70.08M | 581.11M |
| % Held by Insiders | 0.00% | 0.01% |
| % Held by Institutions | 1.02% | 0.88% |
Dividend Analysis & Yield Comparison: Insulet vs Edwards Lifesciences
| Metric | PODD | EW |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |